Compound libraries

The Fragment libraries offer a curated selection of molecular fragments for fragment-based screening applications. These have been sourced from commercial vendors for accessing by Compounds Australia researchers.

The Fragment libraries have been curated for researchers interested in fragment-based drug discovery or probing molecular interactions at a finer scale.

Additional molecular fragments are available within the Academic library, including ~1,000 compounds from the University of Adelaide's fragment collection.

Subsets include:

• Electrophilic Covalent Probe Library (Enamine) – 10 mM
• ’Novel Fragment Diversity Set (Life Chemicals) – 1,280 fragments at 100 mM
• ChemBridge Fragment Library (purchased in 2017) – 50mM / 100mM

Storage and access

• Access is charged on a per plate basis (cherrypicking or plate replication)
• Stored in optimal conditions as 10mM, 50mM or 100mM solutions in 100% DMSO (Concentrations are depending on sub-library)
• Available in assay-ready formats only (volumes 2.5–1000nL)
• Full libraries or customized subsets available

The Structural Genomics Consortium have shared their high-quality, well-characterised small molecule probe library, which was carefully developed in cooperation with pharmaceutical companies and academic partners.

Probes included in the DCP library must meet high standards for potency, selectivity, and cellular on-target activity, with that comprehensive characterisation data provided to users:

• Potency: In vitro potency (IC₅₀ or K_D) <100 nM.
• Selectivity: > 30-fold selectivity within the target family.
• Cellular Activity: On-target activity in cells <1 µM.

Each probe is accompanied by a structurally similar, inactive negative control compound (where possible) as well as dosing information to inform appropriate experimental design.

The collection covers a wide range of targets, including:

• Kinases
• GPCRs
• Ion channels
• Hydrolases
• Proteases
• GTPases

Learn more about the well-characterised tool compounds from the Structural Genomics Consortium, or contact Compounds Australia to request.

Storage and access

• Access is charged on a per plate basis (cherrypicking or plate replication).
• Stored in optimal conditions as 5 mM solutions in 100% DMSO, with appropriate dosing information available to inform experimental design.
• Available in assay-ready formats (volumes 2.5 nL – 5 µL). Dry samples available for follow-up studies directly from the Structural Genomics Consortium.
• Full collection or customised subsets available.

Boehringer Ingelheim’s open innovation portal, OpnMe^® has shared their collection of high-quality, well-characterized tool compounds with Compounds Australia.

The opnMe^® collection contains over 90 molecules rigorously quality-controlled and carefully selected for relevance to key disease research topics.

Wide range of mechanisms of action against contemporary targets, including

• PROTACs,
• GPCRs,
• nuclear receptors,
• epigenetic targets,
• membrane transporters,
• ion channels,
• kinases,
• RNA targets, and
• enzymes.

Each molecule in the opnMe^® collection comes with a comprehensive profile that includes structural data, a rich pharmacology package, and selectivity data set. Many of the molecules additionally come with negative control molecules, to assist with characterization and target validation.

View the collection on Smart Compounds or learn more about the well-characterised tool compounds from opnMe^®.

Storage and access

• Access is charged on a per plate basis (cherrypicking or plate replication).
• Stored in optimal conditions as 5 mM solutions in 100% DMSO.
• Available in assay-ready formats (volumes 2.5 nL – 5 µL). Dry samples available for follow-up studies directly from opnMe.
• Full collection or customised subsets available.

A unique library deposited by Australian biotech company Advanced Molecular Technologies to seed collaborations with biologists. The set is designed to develop chemoselective drugs, theranostics and diagnostics that are activated in cells under increased oxidative stress, such as is seen in cancer, viral infections, inflammation, ischemia/reperfusion injury, and Alzheimer’s and Parkinson’s diseases.

• Composed of 96 parent drugs – both known and new – in the ‘active’ chemical state.
• Advanced Molecular Technologies has propriety chemical processes to synthesise the prodrug forms of the molecules, which will be converted to the active form when they reach their site of action.
• The new technologies can also be used to enhance site selective delivery/active uptake into target sites before being converted to the active forms.
• If your screening identifies a hit, you have a unique opportunity to collaborate with Advanced Molecular Technologies to develop novel lead molecules against your target.
• Chemoselective drugs are a validated strategy to develop drugs with improved safety, increased activity and selectivity by reducing on-target activity outside of the site of action.
• All compounds are solubilised at 5 mM in DMSO.
• The prodrugs can be modified to modulate solubilities.

Download library information